Metabolism of the new MAO-A inhibitor brofaromine in poor and extensive metabolizers of debrisoquine.
Jedrychowski
M
M
Human Pharmacology Institute, CIBA-GEIGY GmbH, Tübingen, Germany.
Feifel
N
N
Bieck
P R
PR
Schmidt
E K
EK
D000284:Administration, Oral; D000328:Adult; D002851:Chromatography, High Pressure Liquid; D019389:Cytochrome P-450 CYP2D6; D003577:Cytochrome P-450 Enzyme System / Q000172:deficiency; D003647:Debrisoquin / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism* / Q000652:urine; D005260:Female; D006801:Humans; D008297:Male; D006899:Mixed Function Oxygenases / Q000172:deficiency; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism* / Q000652:urine; D010880:Piperidines / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism* / Q000652:urine
D008996:Monoamine Oxidase Inhibitors; D010880:Piperidines; C038213:brofaromine; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D019389:Cytochrome P-450 CYP2D6; D003647:Debrisoquin